Cargando…
Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia
INTRODUCTION: While allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be a curative regimen for acute myeloid leukemia (AML), relapse of AML remains a serious risk post-transplantation. Once relapsed, salvage options are limited and management of AML is difficult. Here we designed a...
Autores principales: | Feng, Yimei, Chen, Ting, Zhang, Yun, Yao, Han, Wang, Ping, Wang, Lu, Cassady, Kaniel, Zou, Zhongmin, Liu, Yuqing, Zhao, Lu, Gao, Lei, Zhang, Xi, Kong, Peiyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332158/ https://www.ncbi.nlm.nih.gov/pubmed/37435080 http://dx.doi.org/10.3389/fimmu.2023.1182251 |
Ejemplares similares
-
Case Report: PD-1 Blockade Combined Autologous Hematopoietic Stem Cell Transplantation With Modified BEAM Regimen Containing High-Dose Cytarabine to Treat R/R Hodgkin's Lymphoma
por: Wang, Xiaoqi, et al.
Publicado: (2021) -
The Addition of Sirolimus to GVHD Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation: A Meta-Analysis of Efficacy and Safety
por: Chen, Xiaoli, et al.
Publicado: (2021) -
TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair
por: Feng, Yimei, et al.
Publicado: (2019) -
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia
por: Craddock, Charles, et al.
Publicado: (2019) -
Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial
por: Schroeder, Thomas, et al.
Publicado: (2023)